Steven Coutre

Clinical Focus

• Cancer > Hematology
• Cancer > Hematology > Leukemia - Acute and Chronic
• Hematology
• Idiopathic Hypereosinophillic Syndrome
• Leukemia

Administrative Appointments

• Acute Myeloid Leukemia Panel, National Comprehensive Cancer Network (1998 - present)
• Leukemia Committee, Southwest Oncology Group (1996 - present)
• Director of Hematology Clinic, Stanford University (1996 - present)

Honors and Awards

• Timothy F. Beckett, Jr. Award for Excellence in Clinical Teaching, Stanford University (1990)
• Bernard Cohen Postdoctoral Fellowship, Stanford University (1991)
• Division Teaching Award, Stanford University (2002)

Professional Education

Graduate & Fellowship Program Affiliations

• Medicine

Web Site Links

• Hematology Division

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. View Full Information

Research Interests

My work emphasizes both patient care and translational research. I focus on both the hematologic malignancies as well as conditions such as anemia and blood clotting disorders. Our program offers novel treatments for many of these conditions in the context of clinical trials. We also have comprehensive laboratory services offering the most up-to-date testing for both the diagnosis and management of complex hematologic problems. Recent clinical protocols involved the treatment of acute myeloid leukemia, acute lymphoid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, multiple myeloma, prolymphocytic leukemia, hypereosinophilic syndrome, systemic mastocytosis and heparin-induced thrombocytopenia.

Clinical Trials

• A Study to Assess BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients Recruiting
• Azacitidine and Gemtuzumab in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Recruiting
• Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotexate or Observation in Treating Patients With Acute Promyelocytic Leukemia Recruiting
• Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML Recruiting
• Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin Followed By High-Dose Cytarabine Followed By Either Gemtuzumab Ozogamicin or No Additional Therapy in Treating Patients With Previously Untreated De Novo Acute Myeloid Leukemia Recruiting

Publications

• Optimizing therapy for acute myeloid leukemia. Kohrt HE, Coutre SE. J Natl Compr Canc Netw. 2008; 6 (10): 1003-16
• Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Ottmann O, Dombret H, Martinelli G, Simonsson B, Guilhot F, Larson RA, Rege-Cambrin G, Radich J, Hochhaus A, Apanovitch AM, Gollerkeri A, Coutre S. Blood. 2007; 110 (7): 2309-15
• Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. DeAngelo DJ, Yu D, Johnson JL, Coutre SE, Stone RM, Stopeck AT, Gockerman JP, Mitchell BS, Appelbaum FR, Larson RA. Blood. 2007; 109 (12): 5136-42
• Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S, Hochhaus A, Guilhot F, Saglio G, Apperley J, Ottmann O, Shah N, Erben P, Branford S, Agarwal P, Gollerkeri A, Baccarani M. Blood. 2007; 109 (8): 3207-13
• Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Gotlib J, Berubé C, Growney JD, Chen CC, George TI, Williams C, Kajiguchi T, Ruan J, Lilleberg SL, Durocher JA, Lichy JH, Wang Y, Cohen PS, Arber DA, Heinrich MC, Neckers L, Galli SJ, Gilliland DG, Coutré SE. Blood. 2005; 106 (8): 2865-70